Does prior authorization of sibutramine improve medication compliance or weight loss?

Obesity Research

Volumn 13, Issue 1, 2005, Pages 86-92

  Risser, Joseph A ^a   Vash, Peter D ^a,b   Nieto, Lurline ^a  

^a Lindora Medical Clinics   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Compliance; Pharmacotherapy; Prior authorization; Sibutramine; Weight loss

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; SIBUTRAMINE;

ARTICLE; DRUG EFFECT; ECONOMICS; FEMALE; HEALTH INSURANCE; HUMAN; LOW CALORY DIET; MALE; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; PHYSIOLOGY; RETROSPECTIVE STUDY; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CYCLOBUTANES; DIET, REDUCING; FEMALE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 20644449866     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2005.11     Document Type: Article

References (16)

1. Speroff T, Dawson N, Speroff L, et al. A risk-benefit analysis of elective bilateral oophorectomy: effect on changes in compliance with estrogen therapy on outcome. Am J Obstet Gynecol. 1991;164:165-74.
2. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agents Dis. 1994;3:266-73.
3. MacDougall LG, Wilson TD, Cohn R, Shuenyane EN, McElligott SE. Compliance with chemotherapy in childhood leukaemia in Africa. S Afr Med J. 1989;75:481-4.
4. Berry EM. Why is the treatment of cancer more successful than that of obesity? Publ Health Rev. 1996;24:147-63.
5. Coombs JH, Cornish L, Hiller P, Smith DG. Compliance and refill pattern behavior with HMG-CoA reductase inhibitors after acute myocardial infarction. Manag Care Interface. 2002;15:54-60.
6. DTC-advertised drugs are more likely to be subject to PAR. Drug Cost Manag Rep. 2002;3:1.
7. Lueck S. Drug prices far outpace inflation: report by consumer group highlights cost pressures faced by senior citizens. Wall Street J (Eastern ed). 2003;JuIy 10:D2.
8. Senate votes to help states get Rx discounts. (Rx Drugs). Mede Health. 2002;56:2.
9. Mintzes B, Barer ML, Kravitz RL, et al. How does direct to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Can Med Assoc J. 2003;169:405-12.
10. Linné Y, Hemmingsson E, Adolfsson B, Ramsten J, Rössner S. Patient expectations of obesity treatment-the experience from a day-care unit. Int J Obes Relat Metab Disord. 2002;26:739-41.
11. Stuart RB. Behavioral control of overeating. Res Therap. 1967;5:357-63.
12. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001;23:1311-20.
13. Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res. 1999;7:523-31.
14. Oster G, Thompson D, Edelsberg J, Bird AP, Colditz GA. Lifetime health and economic benefits of weight loss among obese persons. Am J Publ Health. 1999;89:1536-42.
15. Björvell H, Rössner S. Short communication: a ten-year follow-up of weight change in severely obese subjects treated in a combined behavioural modification programme. Int J Obes Relat Metab Disord. 1992;16:623-5.
16. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288:1733-9.